Cocrystal Pharma, Inc. (COCP) Stock

Cocrystal Pharma, Inc. (COCP) is a Healthcare stock trading at $1.14 (as of 2026-08-21), with a market capitalization of $21.86M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Understand Cocrystal Pharma, Inc.: how it makes money

Cocrystal Pharma discovers and develops antiviral therapeutic drug candidates for serious or chronic viral diseases, aiming to make money by advancing its pipeline into clinical development that could support future treatment commercialization.

Because the company is focused on R and D for antiviral candidates in Phase II and preclinical stages, its path to profit is structurally tied to clinical and development milestones rather than current product revenue.

Business quality (Weak): Clear pipeline focus, but limited segment detail and only one disclosed operating metric, so investors mainly track progress signals rather than business-line performance.

Bull case

Pipeline progress on HCV therapy: CC-31244, a hepatitis C virus non-nucleoside polymerase inhibitor, has completed Phase II a clinical trial to treat HCV infection.
Influenza candidate is advancing in the pipeline: CC-42344, a PB2 inhibitor, is in preclinical development trials for treating influenza infection.

Bear case

Development-stage uncertainty: Some candidates are still in preclinical development, which can face setbacks before any potential late-stage success.
No reported revenue in the latest period: For the period ended 2026-03-31, reported revenue is 0.0B, leaving the company reliant on ongoing development rather than operating cash flow.

Valuation — source: SEC EDGAR (first-party)
Price	$1.14
Market Cap	$21.86M
Price / Book	20.94
Price / Sales	20.76
FCF Yield	-29.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.01M
Net Margin	-479.0%

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($258444.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Sam Lee
Employees	11
Country	US
IPO Date	2012-02-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.